# Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression

> **NCT00622245** · PHASE2 · TERMINATED · sponsor: **H. Lundbeck A/S** · enrollment: 166 (actual)

## Conditions studied

- Depression in Patients With Bipolar Disorder

## Interventions

- **DRUG:** Lu AA34893
- **DRUG:** Quetiapine fumarate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00622245
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-01
- **Primary completion:** 2009-01
- **Final completion:** 2009-11
- **Target enrollment:** 166 (ACTUAL)
- **Why stopped:** Human metabolite not yet covered sufficiently by nonclinical data
- **Last updated:** 2010-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00622245

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00622245, "Efficacy and Safety of Lu AA34893 in Patients With Bipolar Depression". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00622245. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*